Compare
Yubo International Biotech Ltd vs Nexalin Technology, Inc. vs Positron Corp vs iTonic Holdings Ltd
| Latest fiscal year | Yubo International Biotech Ltd YBGJ | Nexalin Technology, Inc. NXL | Positron Corp POSC | iTonic Holdings Ltd ITOC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $12.4K | $301.6K | $461.5K | $523.0K |
| Revenue growth (YoY) | +256.0% | +78.8% | -21.5% | +16.7% |
| Gross margin | 66.1% | 79.7% | -458.2% | 62.6% |
| Operating margin | n/m | n/m | n/m | -991.7% |
| Net margin | n/m | n/m | n/m | -974.7% |
| Net income | -$1.08M | -$8.22M | -$10.60M | -$5.10M |
| EPS (Diluted) | -$0.01 | -$0.50 | -$0.34 | -$0.32 |
| Operating cash flow | -$842.8K | -$4.96M | -$4.70M | -$3.23M |
| Free cash flow | n/a | n/a | n/a | -$3.24M |
| Cash & equivalents | $8.1K | $654.8K | n/a | $1.49M |
| Total assets | $847.1K | $4.64M | $4.00M | $9.10M |
| Total liabilities | $2.79M | $887.3K | $2.56M | $969.8K |
| Shareholders' equity | -$1.95M | $3.75M | $1.44M | $6.12M |
| Return on year-end equity | n/a | -219.4% | -734.4% | -83.3% |
| Shares outstanding | n/a | 19.19M | 32.80M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Yubo International Biotech Ltd | Nexalin Technology, Inc. | Positron Corp | iTonic Holdings Ltd |
|---|---|---|---|---|
| Latest | $12.4K Ended 2025-12-31 | $301.6K Ended 2025-12-31 | $461.5K Ended 2025-12-31 | $523.0K Ended 2025-12-31 |
| 1 year earlier | $3.5K Ended 2024-12-31 | $168.7K Ended 2024-12-31 | $587.5K Ended 2024-12-31 | $448.2K Ended 2024-12-31 |
| 2 years earlier | $604.7K Ended 2023-12-31 | $110.7K Ended 2023-12-31 | n/a | $628.6K Ended 2023-12-31 |
| 3 years earlier | $104.3K Ended 2022-12-31 | $1.32M Ended 2022-12-31 | n/a | $679.8K Ended 2022-12-31 |
| 4 years earlier | $1.24M Ended 2021-12-31 | $144.1K Ended 2021-12-31 | n/a | n/a |